Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Modalis TherapeuticsTSE:4883 +3.03%20 PB Ratio is 1.12 as of Jul. 14, 2026, which is 36% below its 10-year median of 1.74. GuruFocus rates TSE:4883 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 921 Drug Manufacturers companies, Modalis Therapeutics ranks better than 71.88% on this metric.
Modalis Therapeutics Corp stock PB Ratio (=1.09) is close to 1-year high of 1.09.
The historical rank and industry rank for Modalis Therapeutics's PB Ratio or its related term are showing as below:
TSE:4883'
s PB Ratio Range Over the Past 10 Years
Min: 0.3 Med: 1.74 Max: 21.38
Current: 1.12
During the past 8 years, Modalis Therapeutics's highest PB Ratio was 21.38. The lowest was 0.30. And the median was 1.74.
TSE:4883's PB Ratio is ranked better than 71.88% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs TSE:4883: 1.12
During the past 12 months, Modalis Therapeutics's average Book Value Per Share Growth Rate was -37.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -31.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -33.70% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Modalis Therapeutics was 58.80% per year. The lowest was -42.50% per year. And the median was -31.50% per year.
Back to Basics: PB Ratio
Modalis Therapeutics (TSE:4883) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Modalis Therapeutics PB Ratio Related Terms
Modalis Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Modalis Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Modalis Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Modalis Therapeutics PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Modalis Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Modalis Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Modalis Therapeutics (TSE:4883) has a PB Ratio of 1.12 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Modalis Therapeutics and its competitors. This is 36% below median its historical median of 1.74. Over the past decade, Modalis Therapeutics' PB Ratio has ranged from 0.30 to 21.38. According to the industry distribution chart, Modalis Therapeutics ranks #259 out of 921 companies in the Drug Manufacturers industry, placing it in the top 28.1%.
Is Modalis Therapeutics' PB Ratio too high?
Modalis Therapeutics' current PB Ratio of 1.12 is 36% below median its 10-year median of 1.74. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 21.38. The Drug Manufacturers industry median PB Ratio is 1.90. Modalis Therapeutics' value of 1.12 is 41.1% below this industry median. Based on the distribution chart, Modalis Therapeutics ranks #259 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Modalis Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Modalis Therapeutics' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Modalis Therapeutics ranks #259 out of 921 companies for PB Ratio. This puts Modalis Therapeutics in the upper half of its industry. The industry median PB Ratio is 1.90. Modalis Therapeutics' value of 1.12 is 41.1% below this benchmark. Historically, Modalis Therapeutics' own PB Ratio has ranged from 0.30 to 21.38 over the past decade. While the company's 10-year median is 1.74 vs. the industry median of 1.90, Modalis Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Modalis Therapeutics's current PB Ratio of 1.12 is 41.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Modalis Therapeutics and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Modalis Therapeutics's current PB Ratio is 1.12, which is 36% below median its own 10-year median of 1.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modalis Therapeutics stock overvalued right now?
Modalis Therapeutics (TSE:4883) has a current PB Ratio of 1.12. The current PB Ratio is 1.12, which is 36% below median its 10-year median of 1.74 and 41.1% below the Drug Manufacturers industry median of 1.90. Modalis Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Modalis Therapeutics (TSE:4883), the current PB Ratio is 1.12 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in the pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.
20GF Score
Get the complete analysis for TSE:4883
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4883 has been successfully added to your 
